What is Wedbush’s Forecast for ZNTL FY2024 Earnings?

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Investment analysts at Wedbush boosted their FY2024 earnings per share estimates for shares of Zentalis Pharmaceuticals in a research note issued on Tuesday, November 12th. Wedbush analyst R. Driscoll now expects that the company will post earnings of ($2.33) per share for the year, up from their previous forecast of ($2.83). Wedbush currently has a “Neutral” rating and a $4.00 target price on the stock. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($3.02) per share. Wedbush also issued estimates for Zentalis Pharmaceuticals’ Q4 2024 earnings at ($0.66) EPS, Q1 2025 earnings at ($0.69) EPS, Q2 2025 earnings at ($0.70) EPS, Q3 2025 earnings at ($0.56) EPS, Q4 2025 earnings at ($0.57) EPS, FY2025 earnings at ($2.48) EPS, FY2026 earnings at ($2.22) EPS, FY2027 earnings at ($1.67) EPS and FY2028 earnings at ($0.88) EPS.

Several other brokerages have also issued reports on ZNTL. Oppenheimer reiterated an “outperform” rating and set a $20.00 price target on shares of Zentalis Pharmaceuticals in a report on Monday, September 16th. HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of Zentalis Pharmaceuticals in a report on Monday, August 12th. Five investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $10.25.

Zentalis Pharmaceuticals Trading Up 0.8 %

Shares of Zentalis Pharmaceuticals stock opened at $3.95 on Friday. Zentalis Pharmaceuticals has a 52-week low of $2.66 and a 52-week high of $18.07. The stock has a 50-day simple moving average of $3.41 and a 200-day simple moving average of $5.52.

Institutional Trading of Zentalis Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the company. Erste Asset Management GmbH bought a new stake in Zentalis Pharmaceuticals in the third quarter valued at $37,000. Paloma Partners Management Co acquired a new position in Zentalis Pharmaceuticals in the third quarter valued at about $37,000. Anfield Capital Management LLC acquired a new position in Zentalis Pharmaceuticals in the second quarter valued at about $40,000. Aigen Investment Management LP acquired a new position in Zentalis Pharmaceuticals in the third quarter valued at about $41,000. Finally, Capstone Investment Advisors LLC bought a new stake in shares of Zentalis Pharmaceuticals in the third quarter worth about $48,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.